美高梅中國(02282.HK)績後造好 升逾2%
美高梅中國(02282.HK)在公布季績後,股價逆市造好,今日(31日)高開1.03%,最高見16.06元。現報15.98元,升2.44%,成交186.2萬股,涉資2,938.38萬元。
美高梅中國第二季經調整EBITDA按年增長2.8%至25.11億元,按季比較增長6.1%,創季度新高。期內娛樂場收益錄9.77億美元,按年增長10%集團整體市場份額達16.6%,當中澳門美高梅及美獅美高梅市場份額約為6.2%及10.5%。
美高梅中國透露,第二季酒店旅客量按年上升12%,遠高於疫情前水平,達到2019年同期的175%。本季美高梅中國整體日均博彩毛收入達1.112億澳門元,按年上升12%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.